A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

Autor: Ott PA; Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. Electronic address: patrick_ott@dfci.harvard.edu., Hu-Lieskovan S; Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Chmielowski B; Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Govindan R; Washington University School of Medicine, St. Louis, MO, USA., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bhardwaj N; Tisch Cancer Institute, Icahn School of Medicine, New York, NY, USA., Margolin K; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA., Awad MM; Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA., Hellmann MD; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lin JJ; Cancer Center, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA., Friedlander T; Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA., Bushway ME; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Balogh KN; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Sciuto TE; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Kohler V; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Turnbull SJ; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Besada R; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Curran RR; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Trapp B; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Scherer J; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Poran A; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Harjanto D; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Barthelme D; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Ting YS; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Dong JZ; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Ware Y; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Huang Y; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Huang Z; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Wanamaker A; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Cleary LD; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Moles MA; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Manson K; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Greshock J; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Khondker ZS; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Fritsch E; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Rooney MS; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., DeMario M; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Gaynor RB; Neon Therapeutics/BioNTech US, Cambridge, MA, USA., Srinivasan L; Neon Therapeutics/BioNTech US, Cambridge, MA, USA. Electronic address: lakshmi.srinivasan@biontech.us.

Publikováno v: Cell [Cell] 2020 Oct 15; Vol. 183 (2), pp. 347-362.e24.